EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, MAY 10, 2016
Media Advisory: To contact Dinesh Khanna, M.D., call Kylie O’Brien at 734-764-2220 or email email@example.com.
To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.5258
In an article appearing in the May 10 issue of JAMA, Dinesh Khanna, M.D., of the University of Michigan Scleroderma Program, Ann Arbor, and colleagues evaluated the efficacy of the drug macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis.
Systemic sclerosis is a chronic multisystem autoimmune disease and multiorgan disease affecting the connective tissue of the skin and several internal organs. Digital ulcers occur in 35 percent to 68 percent of patients with systemic sclerosis and are associated with pain, disfigurement, poor quality of life, and disability. For this study, two clinical trials (DUAL-1, DUAL-2) were conducted in which patients with systemic sclerosis and active digital (finger) ulcers at trial entry were randomly assigned to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily and stratified according to number of digital ulcers at baseline. Macitentan is a drug approved for long-term treatment of pulmonary arterial hypertension.
In DUAL-1, among 289 randomized patients, 226 completed the study. Among 265 patients randomized in DUAL-2, 216 completed the study. The researchers found that macitentan did not reduce the cumulative number of new digital ulcers over 16 weeks compared with placebo. Regardless of treatment, patients had few new digital ulcers, and their overall digital ulcer condition remained stable over 16 weeks.
Adverse events more frequently associated with macitentan than with placebo were headache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection and diarrhea.
“These results do not support the use of macitentan for the treatment of digital ulcers in this patient population,” the authors write.
(doi:10.1001/jama.2016.5258; this study is available pre-embargo at the For The Media website.)
Editor’s Note: DUAL-1 and DUAL-2 were funded by Actelion Pharmaceuticals Ltd. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
# # #